ライフサイエンスコーパス: contralateral breast cancer

1 r carcinoma in situ (LCIS) were followed for contralateral breast cancer.

2 is associated with risk of breast cancer and contralateral breast cancer.

3 and cumulative risks of breast, ovarian, and contralateral breast cancer.

4 rrence of invasive locoregional, distant, or contralateral breast cancer.

5 ugh few had a clinically significant risk of contralateral breast cancer.

6 lower risks of breast cancer recurrence and contralateral breast cancer.

7 free survival, overall survival, and time to contralateral breast cancer.

8 -fold (95% CI, 1.9 to 26.5) elevated risk of contralateral breast cancer.

9 ld (95% CI, 1.03-19.0) increased risk of ER- contralateral breast cancer.

10 y higher risk of developing a second primary contralateral breast cancer.

11 d the absolute occurrence of ipsilateral and contralateral breast cancer.

12 e a substantially reduced risk of developing contralateral breast cancer.

13 ifen might play in the reduction of risk for contralateral breast cancer.

14 ed as potential risk factors for synchronous contralateral breast cancer.

15 Eight women developed a contralateral breast cancer.

16 .22-0.63; p<0.0001), but having no effect on contralateral breast cancer (0.84, 0.45-1.58; p=0.6).

17 for disease recurrence or the occurrence of contralateral breast cancer, 0.66; P=0.01 by a two-sided

18 cancer specific mortality (0.72, 0.45-1.16), contralateral breast cancer (1.18, 0.64-2.16), or depres

19 Among the 704 participants with contralateral breast cancer, 108 (15.3%) were identified

20 ed 5 years reduces the risk of recurrence or contralateral breast cancer 15 years after starting trea

21 ion, and 5.6% (5.5% to 5.6%) had developed a contralateral breast cancer, 3.1% (3.0% to 3.2%) more th

22 es (324 vs 375, 0.86, 0.74-0.99, p=0.04) and contralateral breast cancers (35 vs 59, 42% reduction, 1

23 tases (89% v 92%, respectively; P = .16), or contralateral breast cancer (6% v 6%, respectively; P =

24 ving disease recurrence or the occurrence of contralateral breast cancer (67 with letrozole and 98 wi

25 ated that desires to decrease their risk for contralateral breast cancer (98%) and improve survival (

26 Contralateral breast cancer accounts for around 60% of t

27 vivors had an increased risk of metachronous contralateral breast cancer (adjusted hazard ratio [HR],

28 Information is limited on the risk of contralateral breast cancer after a diagnosis of breast

29 the hazard ratio (HR) for the occurrence of contralateral breast cancer after CPM was 0.03 (95% CI,

30 d smoking on risk of second primary invasive contralateral breast cancer among breast cancer survivor

31 47 years; IQR, 40-55 years) eligible for the contralateral breast cancer analysis, 426 were diagnosed

32 ve invasive breast cancer and second primary contralateral breast cancer and 728 matched control wome

33 ated breast cancer are at increased risk for contralateral breast cancer and ovarian cancer and there

34 Probabilities for developing contralateral breast cancer and ovarian cancer, dying fr

35 Aromatase inhibitors prevent more contralateral breast cancers and cause fewer side effect

36 y with increased uterine cancer (but reduced contralateral breast cancer), and chemotherapy with incr

37 seems to protect against the development of contralateral breast cancer, and although women who unde

38 mic heart disease, cerebrovascular diseases, contralateral breast cancer, and depression.

39 WBI and 10 PBI; P = .28), 20 patients had a contralateral breast cancer, and eight patients had dist

40 ated PRS have an elevated risk of developing contralateral breast cancer, and that the PRS can consid

41 The risks of subsequent contralateral breast cancer are substantial for women wh

42 This study assessed the risk of subsequent contralateral breast cancer associated with carrying a B

43 ns were significantly more likely to develop contralateral breast cancer at 5 years (31% v 4%, P=.000

44 rolled in the trial who did not have a known contralateral breast cancer at the time of surgical plan

45 Given these patients' high risk for contralateral breast cancer, bilateral mastectomy is inc

46 ctic mastectomy [CPM]), although the risk of contralateral breast cancer (CBC) has decreased in recen

47 reast cancer survivors at risk of developing contralateral breast cancer (CBC) is increasing.

48 Contralateral breast cancer (CBC) is the most frequent n

49 enes other than BRCA1, BRCA2, and CHEK2 with contralateral breast cancer (CBC) risk and breast cancer

50 ersus routine surveillance as an alternative contralateral breast cancer (CBC) risk management strate

51 PRS of 313 germline variants (PRS(313)) and contralateral breast cancer (CBC) risk.

52 Rates of IBTR, distant recurrence, and contralateral breast cancer (CBC) were among the end poi

53 idences of locoregional recurrence (LRR) and contralateral breast cancer (CBC) were assessed with com

54 er diagnosis, roughly 5% of patients develop contralateral breast cancer (CBC).

55 tify factors predictive of HRL and/or occult contralateral breast cancer (CBC).

56 fy genetic and environmental determinants of contralateral breast cancer (CBC).

57 er diagnosis, roughly 5% of patients develop contralateral breast cancer (CBC).

58 netic resonance imaging (MRI) detects occult contralateral breast cancers (CBCs) in women with breast

59 tes of in-breast tumor recurrence (IBTR) and contralateral breast cancers (CBCs).

60 lower risks of breast cancer recurrence and contralateral breast cancer compared with placebo.

61 ation Epidemiology [WECARE]) of asynchronous contralateral breast cancer conducted during the period

62 ancer and are judged to be at high risk of a contralateral breast cancer, contralateral risk-reducing

63 Contralateral breast cancer developed in 0.5% of women w

64 Contralateral breast cancer developed in 2.7% of women w

65 his nested case-control study, patients with contralateral breast cancer diagnosed 1 year or more aft

66 ancer, 109 with ovarian cancer, and 245 with contralateral breast cancer during follow-up.

67 rature review of the risk of ipsilateral and contralateral breast cancer events among breast cancer s

68 w established a low risk for ipsilateral and contralateral breast cancer events in most older breast

69 y had above-average risks of ipsilateral and contralateral breast cancer events, most did not have an

70 and 10-year cumulative) risks of developing contralateral breast cancer following a first invasive b

71 The relative risk of contralateral breast cancer for BRCA1 mutation carriers

72 e age-specific risks of breast, ovarian, and contralateral breast cancer for mutation carriers and to

73 Letrozole reduced contralateral breast cancer frequency in the first 10 ye

74 essed the long-term risks of ipsilateral and contralateral breast cancer in a cohort of young women w

75 tion is available on the subsequent risks of contralateral breast cancer in mutation carriers.

76 The annual incidence rate of contralateral breast cancer in the letrozole group was 0

77 stic accuracy for additional ipsilateral and contralateral breast cancer in women with nondense breas

78 mary endpoints were rates of ipsilateral and contralateral breast cancer, in relation to germline BRC

79 al prophylactic mastectomy (CPM) in reducing contralateral breast cancer incidence and breast cancer

80 silateral breast tumour recurrence rates and contralateral breast cancer incidence are scarce, but to

81 Regarding contralateral breast cancer incidence, there were six ev

82 (local, regional, or distant recurrence, or contralateral breast cancer, invasive disease, or ductal

83 The true risk of contralateral breast cancer is not associated with the d

84 In particular, the risk of a contralateral breast cancer is reviewed to help guide th

85 sk of the relatively uncommon outcome of ER- contralateral breast cancer may now need to be tallied a

86 isk of hormone receptor-specific subtypes of contralateral breast cancer (n = 303 ER+ and n = 52 ER-

87 ntinued until the first event of recurrence, contralateral breast cancer, new primary malignant neopl

88 oking were all positively related to risk of contralateral breast cancer (odds ratio [OR], 1.4; 95% C

89 en for >or=5 years had a reduced risk of ER+ contralateral breast cancer [odds ratio, 0.4; 95% confid

90 oophorectomy was not associated with risk of contralateral breast cancer or IBTR.

91 ory of HRT did not have an increased risk of contralateral breast cancer or second non-breast cancer

92 Participants previously diagnosed with contralateral breast cancer or unilateral breast cancer

93 in regional recurrence, distant metastases, contralateral breast cancers, or new breast cancers were

94 ipsilateral breast tumor recurrence (IBTR), contralateral breast cancer, ovarian cancer, and ovarian

95 time to distant recurrence, incidence of new contralateral breast cancer, overall survival, and death

96 regimens, a significant excess incidence of contralateral breast cancer (rate ratio 1.18, SE 0.06, 2

97 Contralateral breast cancer rates are declining as well

98 95% CI, 2.0- to 5.8-fold) increased risks of contralateral breast cancer, respectively.

99 Contralateral breast cancer risk decreased significantly

100 sed on promising data involving reduction of contralateral breast cancer risk in adjuvant studies, se

101 women with low-penetrance mutations (assumed contralateral breast cancer risk of 24% and ovarian canc

102 hose with high-penetrance mutations (assumed contralateral breast cancer risk of 65% and ovarian canc

103 , smoking, and alcohol consumption influence contralateral breast cancer risk, affording breast cance

104 een these three exposures and second primary contralateral breast cancer risk.

105 use for <5 years was not associated with ER- contralateral breast cancer risk.

106 ts, the current evidence for ipsilateral and contralateral breast cancer risks in older survivors of

107 Secondary end points were overall survival, contralateral breast cancer, second primary cancer, and

108 The incidence of contralateral breast cancer seems to be reduced signific

109 silateral recurrences, nine (29.0%) were new contralateral breast cancers, six (19.4%) were distant r

110 ast examination and mammography in detecting contralateral breast cancer soon after the initial diagn

111 sease-free survival and a lower incidence of contralateral breast cancer than those with placebo, but

112 For contralateral breast cancer, the cumulative risk 20 year

113 Efficacy of letrozole versus tamoxifen for contralateral breast cancer varied significantly over ti

114 a trend toward higher risk for relatives of contralateral breast cancer vs unilateral breast cancer

115 the 20-year radiation-related excess risk of contralateral breast cancer was estimated to increase fr

116 The absolute excess risk of contralateral breast cancer was greater in younger than

117 r who underwent breast MR imaging at which a contralateral breast cancer was not identified, patient

118 arly dependent on TN status, but the risk of contralateral breast cancer was not.

119 The risk of contralateral breast cancer was significantly reduced (h

120 e corresponding risks of any recurrence or a contralateral breast cancer were 17%, 22%, and 26%, resp

121 For the 357 postmenopausal women, 50.3 contralateral breast cancers were predicted, whereas onl

122 ers more accurately perceived their risk for contralateral breast cancer, whereas women without a kno

123 Life-tables for contralateral breast cancers, which consider age at firs

124 even patients were diagnosed with subsequent contralateral breast cancer, yielding 5- and 10-year act